Health economist Tomas Philipson joins Jupiter Neurosciences (JUNS) board with option-based pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Jupiter Neurosciences appointed Tomas J. Philipson, Ph.D., a 64-year-old health care economist with extensive academic, government, and industry experience, to its Board of Directors effective June 26, 2026. He will serve until the next annual stockholder meeting, unless he departs earlier.
He was also appointed to the Board’s Audit Committee and Compensation Committee. In lieu of standard cash fees for non-employee directors, he will receive stock options, aligning his compensation with the company’s long-term performance.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director age: 64 years
Sign-on option grant: 90,000 shares
Equity in lieu of cash fees: 446,428 shares
+3 more
6 metrics
Director age
64 years
Age of Tomas J. Philipson
Sign-on option grant
90,000 shares
Option to purchase common stock, sign-on grant
Equity in lieu of cash fees
446,428 shares
Option to purchase common stock replacing retainers and fees
Vesting period
36 months
Quarterly vesting schedule for both option grants
Effective board appointment date
June 26, 2026
Start date of board and committee service
Grant Date for options
June 29, 2026
Date for determining exercise price at fair market value
Key Terms
Audit Committee, Compensation Committee, non-employee directors, annual cash retainer, +1 more
5 terms
Audit Committee financial
"appointed to serve as a member of the Audit Committee and the Compensation Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Compensation Committee financial
"appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
non-employee directors financial
"in lieu of participating in the Company’s standard cash compensation program for non-employee directors"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
annual cash retainer financial
"in lieu of cash compensation otherwise payable as an annual cash retainer and committee fees"
Item 404(a) of Regulation S-K regulatory
"there are no transactions involving Dr. Philipson requiring disclosure under Item 404(a) of Regulation S-K"
FAQ
What board change did Jupiter Neurosciences (JUNS) disclose on June 26, 2026?
Jupiter Neurosciences added Tomas J. Philipson, Ph.D. to its Board of Directors effective June 26, 2026. He will serve until the next annual stockholder meeting and was also appointed to the Audit and Compensation Committees on the same date.
Who is Tomas J. Philipson, the new director at Jupiter Neurosciences (JUNS)?
Tomas J. Philipson is a 64-year-old health care economist with experience in academia, U.S. government, and private sector advisory roles. He previously served as Acting Chairman of the White House Council of Economic Advisers and holds emeritus status at the University of Chicago.
How will Jupiter Neurosciences (JUNS) compensate Tomas J. Philipson for board service?
Instead of cash fees, Jupiter Neurosciences will compensate Tomas J. Philipson with stock options. This equity-based structure replaces the standard cash program for non-employee directors, linking his compensation more directly to the company’s share performance over time.
What stock option sign-on grant did Tomas J. Philipson receive from Jupiter Neurosciences (JUNS)?
He will receive a sign-on option to purchase 90,000 shares of common stock at the fair market value on June 29, 2026. The grant vests in equal quarterly installments over 36 months, subject to his continued service as a director.
What ongoing equity compensation replaces annual cash retainers for Jupiter Neurosciences (JUNS) new director?
In lieu of annual cash retainer and committee fees, Tomas J. Philipson will receive an option to purchase 446,428 shares. The exercise price equals fair market value on June 29, 2026, with vesting in equal quarterly installments over 36 months while he remains a director.
What committees will Tomas J. Philipson serve on at Jupiter Neurosciences (JUNS)?
Effective June 26, 2026, Tomas J. Philipson will serve on the Audit Committee and the Compensation Committee. The filing also lists updated committee compositions, confirming his participation alongside existing chairs and members on these key board committees.